The Real Danger of Substandard and Counterfeit COVID-19 Vaccines

Pharmaceutical Technology, Pharmaceutical Technology, Regulatory Sourcebook, September 2021, Volume 2021 eBook, Issue 3
Pages: 10-14

Low- and middle-income countries are at the greatest risk of receiving substandard and falsified COVID-19 vaccines.

As the COVID-19 pandemic continues, one pressing concern for the industry is ensuring the supply of legitimate COVID-19 vaccines. Now more than ever, the supply chain needs to be secure to ensure the population can have access to legitimate vaccines. But substandard and falsified COVID-19 vaccines—commonly referred to as counterfeit vaccines—continue to be a threat globally.

Regulatory Sourcebook

Read this article in Pharmaceutical Technology’s September 2021 Regulatory Sourcebook eBook.

About the author

Meg Rivers is a senior editor at Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook, September 2021
September 2021
Pages: 10-14

Citation

When referring to this article, please cite it as M. Rivers, “The Real Danger of Substandard and Counterfeit COVID-19 Vaccines," Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).